Therapeutic paths leading from glycemic control to heart failure treatment

Czech version

Authors: Andrej Dukát
Authors‘ workplace: spolueditor
Published in: Forum Diab 2020; 9(2): 93-94
Category: Editorial

Sources

Davies MJ, D’Alessio DA, Fradkin J et al. Mangement of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the study of Diabetes (EASD). Diabetes Care 2018: 41(12): 2669–2701. Dostupné z DOI: <http://dx.doi.org/10.2337/dci18–0033>.

Cosentino F, Grant PJ, Aboyans V et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020; 41(2): 255–323. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehz486>.

Perkovic V, Jardine M, Neal Bet al. [CREDENCE Trial Investigators]. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med 2019: 380(24): 2295–2306. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1811744>.

McMurray JJV et al. [DAPA-HF Trial Committees and Investigators]. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381(21): 1995–2008. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1911303>.

Rossignol P, Hernandez AF, Solomon SD et al. Heart failure drug treatment. Lancet 2019; 393(10175): 1034–1044. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(18)31808–7>.

Bhatt DL, Verma S, Braunwald E. The DAPA-HF Trial: A Momentous Victory in the War against Heart Failure. Cell Metabol 2019: 30(5): 847–849. Dostupné z DOI: <http://dx.doi.org/10.1016/j.cmet.2019.10.008>.